Erratum
https://doi.org/10.11613/BM.2023.031201
Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience
Marija Gomerčić Palčić
; School of Medicine, University of Zagreb, Zagreb, Croatia
Hana Matijaca
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Hematology, Zagreb, Croatia
Ivan Kruljac
; Solmed Group, Department: Poliklinika Solmed, Zagreb, Croatia
Lucija Vusić
Vedran Hostić
; Department of Anesthesiology, Intensive Care Medicine and Pain Management, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Luka Vrbanić
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Pulmonology, Zagreb, Croatia
Fanika Mrsić
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia
Radovan Zrilić
; Polyclinic for Respiratory Diseases, Dom zdravlja Zagreb - Zapad, Zagreb, Croatia
Ivana Ćelap
; Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Croatia
Petar Gaćina
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Hematology, Zagreb, Croatia
Full text: english pdf 35 Kb
page 359-360
downloads: 124
cite
APA 6th Edition
Gomerčić Palčić, M., Matijaca, H., Kruljac, I., Vusić, L., Hostić, V., Vrbanić, L., ... Gaćina, P. (2023). Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience. Biochemia Medica, 33 (3), 359-360. https://doi.org/10.11613/BM.2023.031201
MLA 8th Edition
Gomerčić Palčić, Marija, et al. "Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience." Biochemia Medica, vol. 33, no. 3, 2023, pp. 359-360. https://doi.org/10.11613/BM.2023.031201. Accessed 25 Nov. 2024.
Chicago 17th Edition
Gomerčić Palčić, Marija, Hana Matijaca, Ivan Kruljac, Lucija Vusić, Vedran Hostić, Luka Vrbanić, Fanika Mrsić, Radovan Zrilić, Ivana Ćelap and Petar Gaćina. "Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience." Biochemia Medica 33, no. 3 (2023): 359-360. https://doi.org/10.11613/BM.2023.031201
Harvard
Gomerčić Palčić, M., et al. (2023). 'Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience', Biochemia Medica, 33(3), pp. 359-360. https://doi.org/10.11613/BM.2023.031201
Vancouver
Gomerčić Palčić M, Matijaca H, Kruljac I, Vusić L, Hostić V, Vrbanić L, et al. Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience. Biochemia Medica [Internet]. 2023 [cited 2024 November 25];33(3):359-360. https://doi.org/10.11613/BM.2023.031201
IEEE
M. Gomerčić Palčić, et al., "Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience", Biochemia Medica, vol.33, no. 3, pp. 359-360, 2023. [Online]. https://doi.org/10.11613/BM.2023.031201
Download JATS file
Abstract
Keywords
Hrčak ID:
308778
URI
https://hrcak.srce.hr/308778
Publication date:
15.10.2023.
Visits: 403
*